• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤唾液酸化会阻碍T细胞介导的抗肿瘤反应,同时促进肿瘤相关调节性T细胞的生成。

Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells.

作者信息

Perdicchio Maurizio, Cornelissen Lenneke A M, Streng-Ouwehand Ingeborg, Engels Steef, Verstege Marleen I, Boon Louis, Geerts Dirk, van Kooyk Yvette, Unger Wendy W J

机构信息

Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

出版信息

Oncotarget. 2016 Feb 23;7(8):8771-82. doi: 10.18632/oncotarget.6822.

DOI:10.18632/oncotarget.6822
PMID:26741508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4891003/
Abstract

The increased presence of sialylated glycans on the tumor surface has been linked to poor prognosis, yet the effects on tumor-specific T cell immunity are hardly studied. We here show that hypersialylation of B16 melanoma substantially influences tumor growth by preventing the formation of effector T cells and facilitating the presence of high regulatory T cell (Treg) frequencies. Knock-down of the sialic acid transporter created "sialic acid low" tumors, that grew slower in-vivo than hypersialylated tumors, altered the Treg/Teffector balance, favoring immunological tumor control. The enhanced effector T cell response in developing "sialic acid low" tumors was preceded by and dependent on an increased influx and activity of Natural Killer (NK) cells. Thus, tumor hypersialylation orchestrates immune escape at the level of NK and Teff/Treg balance within the tumor microenvironment, herewith dampening tumor-specific T cell control. Reducing sialylation provides a therapeutic option to render tumors permissive to immune attack.

摘要

肿瘤表面唾液酸化聚糖的增多与预后不良有关,但对肿瘤特异性T细胞免疫的影响却鲜有研究。我们在此表明,B16黑色素瘤的高唾液酸化通过阻止效应T细胞的形成和促进高调节性T细胞(Treg)频率的存在,极大地影响肿瘤生长。敲低唾液酸转运体产生了“低唾液酸”肿瘤,其在体内生长比高唾液酸化肿瘤更慢,改变了Treg/效应T细胞平衡,有利于免疫性肿瘤控制。在发育中的“低唾液酸”肿瘤中,效应T细胞反应增强之前并依赖于自然杀伤(NK)细胞流入和活性的增加。因此,肿瘤高唾液酸化在肿瘤微环境中的NK和Teff/Treg平衡水平上精心策划免疫逃逸,从而削弱肿瘤特异性T细胞控制。减少唾液酸化提供了一种使肿瘤易于受到免疫攻击的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/b3b401f145d0/oncotarget-07-8771-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/6dc8434fd033/oncotarget-07-8771-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/3cc672955562/oncotarget-07-8771-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/755f87d29d02/oncotarget-07-8771-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/b3b401f145d0/oncotarget-07-8771-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/6dc8434fd033/oncotarget-07-8771-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/3cc672955562/oncotarget-07-8771-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/755f87d29d02/oncotarget-07-8771-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f77/4891003/b3b401f145d0/oncotarget-07-8771-g004.jpg

相似文献

1
Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells.肿瘤唾液酸化会阻碍T细胞介导的抗肿瘤反应,同时促进肿瘤相关调节性T细胞的生成。
Oncotarget. 2016 Feb 23;7(8):8771-82. doi: 10.18632/oncotarget.6822.
2
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.索拉非尼缓解肿瘤微环境中效应 T 细胞的细胞内和细胞外抑制作用,增强抗肿瘤免疫。
Int J Cancer. 2014 Jan 15;134(2):319-31. doi: 10.1002/ijc.28362. Epub 2013 Jul 30.
3
Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation.T细胞受体刺激后,B16黑色素瘤中细胞溶解性CD8 + T细胞的积累以及TIS21基因敲除小鼠中成熟T细胞的增殖。
Exp Cell Res. 2014 Oct 1;327(2):209-21. doi: 10.1016/j.yexcr.2014.07.028. Epub 2014 Aug 1.
4
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.唾液酸阻断通过增强 T 细胞介导的肿瘤免疫抑制肿瘤生长。
Cancer Res. 2018 Jul 1;78(13):3574-3588. doi: 10.1158/0008-5472.CAN-17-3376. Epub 2018 Apr 27.
5
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma.白介素-1 受体拮抗剂和化疗对已建立的黑色素瘤中宿主-肿瘤相互作用的影响。
Anticancer Res. 2010 Feb;30(2):345-54.
6
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.IL-33的肿瘤表达通过CD8 + T细胞和自然杀伤细胞抑制肿瘤生长并改变肿瘤微环境。
J Immunol. 2015 Jan 1;194(1):438-45. doi: 10.4049/jimmunol.1401344. Epub 2014 Nov 26.
7
A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.用于神经母细胞瘤临床前免疫研究的 C57Bl/6 小鼠可移植的 TH-MYCN 转基因肿瘤模型。
Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.
8
Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.自然杀伤细胞可阻止CD4+CD25-T淋巴细胞中CD28介导的Foxp3转录。
Exp Hematol. 2007 Mar;35(3):416-25. doi: 10.1016/j.exphem.2006.12.004.
9
Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.表皮生长因子受体(EGFR)特异性抗体耐药的临床前模型:致癌和免疫相关逃逸机制。
Oncogene. 2014 Jun 12;33(24):3129-39. doi: 10.1038/onc.2013.288. Epub 2013 Aug 26.
10
Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.唾液酸修饰的抗原通过抑制T细胞增殖和从头诱导调节性T细胞来诱导耐受。
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3329-34. doi: 10.1073/pnas.1507706113. Epub 2016 Mar 3.

引用本文的文献

1
Targeting Sialidase to PD1 Enhances T cell Function and Tumor Control.将唾液酸酶靶向至程序性死亡蛋白1可增强T细胞功能并控制肿瘤。
ACS Cent Sci. 2025 Jul 4;11(8):1417-1427. doi: 10.1021/acscentsci.5c00510. eCollection 2025 Aug 27.
2
Analysis of cancer-associated glycosyltransferases reveals novel targets of non-small cell lung cancer pathogenesis.癌症相关糖基转移酶的分析揭示了非小细胞肺癌发病机制的新靶点。
Front Oncol. 2025 Jul 11;15:1601368. doi: 10.3389/fonc.2025.1601368. eCollection 2025.
3
Tumor desialylation surpasses anti-PD-L1 checkpoint therapy in restoring anti-tumor immunity in a murine model for colorectal cancer.

本文引用的文献

1
Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.靶向递送唾液酸阻断糖模拟物至癌细胞可抑制转移扩散。
ACS Nano. 2015 Jan 27;9(1):733-45. doi: 10.1021/nn5061964. Epub 2015 Jan 14.
2
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.Siglec-7/9 受体与配体之间的相互作用影响 NK 细胞依赖的肿瘤免疫监视。
J Clin Invest. 2014 Apr;124(4):1810-20. doi: 10.1172/JCI65899. Epub 2014 Feb 24.
3
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
在结直肠癌小鼠模型中,肿瘤去唾液酸化在恢复抗肿瘤免疫方面优于抗PD-L1检查点疗法。
Int J Cancer. 2025 Nov 1;157(9):1948-1962. doi: 10.1002/ijc.70031. Epub 2025 Jul 7.
4
Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.整合的体内功能筛选和多组学分析确定α-2,3-唾液酸化对黑色素瘤维持至关重要。
Sci Adv. 2025 Jul 4;11(27):eadg3481. doi: 10.1126/sciadv.adg3481.
5
Solute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer.溶质载体家族35 A2(SLC35A2)通过MYC介导的途径促进结直肠癌的肿瘤进展。
Int J Med Sci. 2025 Mar 29;22(9):1992-2009. doi: 10.7150/ijms.109767. eCollection 2025.
6
Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.靶向蛋白质修饰:胰腺癌免疫治疗的新方向。
Int J Biol Sci. 2025 Jan 1;21(1):63-74. doi: 10.7150/ijbs.101861. eCollection 2025.
7
Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer.结直肠癌中肿瘤衍生神经节苷脂对抗肿瘤免疫的影响有限。
Glycobiology. 2024 May 26;34(7). doi: 10.1093/glycob/cwae036.
8
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells.表面组学:循环肿瘤细胞免疫逃逸机制发现的新时代。
Mol Oncol. 2024 May 22. doi: 10.1002/1878-0261.13665.
9
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.糖基化靶向:癌症免疫治疗的范式转变。
Int J Biol Sci. 2024 Apr 22;20(7):2607-2621. doi: 10.7150/ijbs.93806. eCollection 2024.
10
T-antigen as a biomarker of progression-free survival in patients with glioblastoma.T 抗原作为胶质母细胞瘤患者无进展生存期的生物标志物。
Ann Clin Transl Neurol. 2024 Jul;11(7):1765-1774. doi: 10.1002/acn3.52082. Epub 2024 May 9.
糖萼工程揭示了基于 Siglec 的 NK 细胞免疫逃逸机制。
Nat Chem Biol. 2014 Jan;10(1):69-75. doi: 10.1038/nchembio.1388. Epub 2013 Nov 24.
4
IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells.调节性 T 细胞控制依赖 IL-2 的 NK 细胞对靶细胞敏感性的调节。
J Exp Med. 2013 Jun 3;210(6):1167-78. doi: 10.1084/jem.20122462. Epub 2013 May 6.
5
ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.ST6Gal-I 蛋白在人类上皮性肿瘤中表达上调,并与正常组织和结肠癌细胞系中的干细胞标志物相关。
Cancer Res. 2013 Apr 1;73(7):2368-78. doi: 10.1158/0008-5472.CAN-12-3424. Epub 2013 Jan 28.
6
Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection.干扰素-γ 通过趋化因子依赖途径介导病毒感染期间自然杀伤细胞的募集。
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E50-9. doi: 10.1073/pnas.1220456110. Epub 2012 Dec 17.
7
The pros and cons of chemokines in tumor immunology.趋化因子在肿瘤免疫学中的利弊。
Trends Immunol. 2012 Oct;33(10):496-504. doi: 10.1016/j.it.2012.05.007. Epub 2012 Jun 20.
8
CD33-related siglecs as potential modulators of inflammatory responses.CD33 相关的 Siglecs 作为炎症反应的潜在调节剂。
Ann N Y Acad Sci. 2012 Apr;1253:102-11. doi: 10.1111/j.1749-6632.2011.06449.x. Epub 2012 Feb 21.
9
Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients.结肠癌患者正常黏膜组织和肿瘤组织中 MUC1 和 CEACAM5 的差异糖基化。
Int J Cancer. 2012 Jul 1;131(1):117-28. doi: 10.1002/ijc.26354. Epub 2011 Nov 28.
10
Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated T cell polarization in a sialic acid linkage-dependent manner.空肠弯曲菌脂寡糖通过唾液酸连接依赖的方式调节树突状细胞介导的 T 细胞极化。
Infect Immun. 2011 Jul;79(7):2681-9. doi: 10.1128/IAI.00009-11. Epub 2011 Apr 18.